Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Iclaprim comparable with vancomycin in nosocomial pneumonia

24 Aug 2017

Iclaprim is as good as vancomycin in the treatment of nosocomial pneumonia, with similar cure rates and safety profile, according to the results of a phase II study.

The study included 70 patients with nosocomial pneumonia suspected or confirmed to be caused by gram-positive pathogens who were randomly assigned to three treatment arms: iclaprim 0.8 mg/kg IV q12h (iclaprim q12h; n=23), iclaprim 1.2 mg/kg IV q8h (iclaprim q8h; n=24), or vancomycin 1 g IV q12h (n=23). Treatment lasted between 7 and 14 days.

There was no significant difference in the baseline and demographic characteristics of patients across the treatment groups.

Likewise, the primary endpoint of clinical cure rate in the intention-to-treat population at test of cure (7 days post-treatment) visit was comparable: 73.9 percent in the iclaprim q12h arm, 62.5 percent in the iclaprim q8h arm and 52.2 percent in the vancomycin arm (iclaprim q12h vs vancomycin, p=0.13; iclaprim q8h vs vancomycin, p=0.47).

The respective death rates within 28 days of treatment initiation were 8.7, 12.5 and 21.7 percent for the iclaprim q12h, q8h and vancomycin arms. No statistically significant differences were noted.

All study drugs were generally well tolerated, with both iclaprim dosing regimens showing a safety profile similar to that of vancomycin.

The current data indicate that iclaprim potentially represents an important new therapeutic option for the treatment of nosocomial pneumonia, and a pivotal clinical trial is warranted to evaluate the drug’s safety and efficacy in this indication, researchers said.

Iclaprim is a novel diaminopyrimidine that inhibits bacterial dihydrofolate reductase. The drug has demonstrated potent in vitro activity against gram-positive pathogens associated with acute bacterial skin and skin structure infections and nosocomial pneumonia, including methicillin-resistant S aureus, vancomycin-intermediate S aureus, vancomycin-resistant Enterococcus species, and Streptococcus species. [Antimicrob Agents Chemother 2009;53:2171–2175; Bioorg Med Chem Lett 2003;13:4217–4221]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.